Pathophysiology of Vascular Calcification in Chronic Kidney Disease
2004/09/16 by Sharon M. Moe, Neal X. Chen · 25 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Parathyroid Disorders and Treatments #Thyroid and Parathyroid Surgery #Dermatological and Skeletal Disorders
paper · doi:10.1161/01.res.0000141775.67189.98
Abstract
Patients with chronic kidney disease (CKD) on dialysis have 2- to 5-fold more coronary artery calcification than age-matched individuals with angiographically proven coronary artery disease. In addition to increased traditional risk factors, CKD patients also have a number of nontraditional cardiovascular risk factors that may play a prominent role in the pathogenesis of arterial calcification, including duration of dialysis and disorders of mineral metabolism. In histological specimens from the inferior epigastric artery of dialysis patients, we have found expression of the osteoblast differentiation factor core binding factor alpha-1 (Cbfa1) and several bone-associated proteins (osteopontin, bone sialoprotein, alkaline phosphatase, type I collagen) in both the intima and medial layers when calcification was present. In cultured vascular smooth muscle cells, the addition of pooled serum from dialysis patients (versus normal healthy controls) accelerated mineralization and increased expression of Cbfa1, osteopontin, and alkaline phosphatase to a similar magnitude as does beta-glycerophosphate alone. However, a lack of inhibitors of calcification may also be important. Dialysis patients with low levels of serum fetuin-A, a circulating inhibitor of mineralization, have increased coronary artery calcification and fetuin-A can inhibit mineralization of vascular smooth muscle cells in vitro. These data support that elevated levels of phosphorus and/or other potential uremic toxins may play an important role by transforming vascular smooth muscle cells into osteoblast-like cells, which can produce a matrix of bone collagen and noncollagenous proteins. This nidus can then mineralize if the balance of pro-mineralizing factors outweighs inhibitory factors.
Cited by
- Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. [europepmc]
- Vitamin D receptor activators can protect against vascular calcification. [europepmc]
- Tibial artery calcification as a marker of amputation risk in patients with peripheral arterial disease. [europepmc]
- Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. [europepmc]
- Dietary phosphorus acutely impairs endothelial function. [europepmc]
- Regulatory mechanisms in vascular calcification. [europepmc]
- α-Lipoic acid attenuates vascular calcification via reversal of mitochondrial function and restoration of Gas6/Axl/Akt survival pathway. [europepmc]
- Survival in patients with poorly compressible leg arteries. [europepmc]
- Vascular calcification: pathophysiology and risk factors. [europepmc]
- Mechanisms and clinical consequences of vascular calcification. [europepmc]
- Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. [europepmc]
- Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. [europepmc]
- Vascular calcification in end-stage renal disease. [europepmc]
- MicroRNAs 29b, 133b, and 211 Regulate Vascular Smooth Muscle Calcification Mediated by High Phosphorus. [europepmc]
- Pyruvate Dehydrogenase Kinase 4 Promotes Vascular Calcification via SMAD1/5/8 Phosphorylation. [europepmc]
- The Role of Shear Stress in Arteriovenous Fistula Maturation and Failure: A Systematic Review. [europepmc]
- Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins. [europepmc]
- The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology. [europepmc]
- The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease. [europepmc]
- Prevalence of Calcification in Human Femoropopliteal Arteries and its Association with Demographics, Risk Factors, and Arterial Stiffness. [europepmc]
- Inhibition of tissue-nonspecific alkaline phosphatase protects against medial arterial calcification and improves survival probability in the CKD-MBD mouse model. [europepmc]
- Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases. [europepmc]
- Arterial Stiffness: A Focus on Vascular Calcification and Its Link to Bone Mineralization. [europepmc]
- Mechanisms of the Osteogenic Switch of Smooth Muscle Cells in Vascular Calcification: WNT Signaling, BMPs, Mechanotransduction, and EndMT. [europepmc]
- ERK1/2 inhibition reduces vascular calcification by activating miR-126-3p-DKK1/LRP6 pathway. [europepmc]
Related